<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265980</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA5988</org_study_id>
    <secondary_id>R01DK064773</secondary_id>
    <nct_id>NCT00265980</nct_id>
  </id_info>
  <brief_title>Leptin in Human Energy and Neuroendocrine Homeostasis</brief_title>
  <official_title>Leptin in Human Energy and Neuroendocrine Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous work in our laboratory, and many others, has shown that body weight is regulated.
      When anyone, fat or thin, tries to maintain a reduced body weight, many systems affecting
      energy balance (skeletal muscle, neuroendocrine, and autonomic systems) conspire to slow
      metabolic rate thus favoring the regain of lost weight. Individuals with leptin deficiency
      are remarkably similar to weight-reduced individuals. Their metabolism, thyroid hormones, and
      sympathetic nervous system activity are all low despite their obesity. While administration
      of leptin to leptin-deficient humans results in substantial weight loss and increases in
      energy expenditure. However, leptin administration to leptin-sufficient humans at usual body
      weight has little or no effect on weight unless given in doses 10-20 times what would be
      considered to be in the normal physiological range. This study examines the hypothesis that
      leptin is &quot;read&quot; by various systems regulating energy balance as an indicator of how much
      energy we have stored and that the body perceives the weight-reduced state as a condition of
      relative leptin insufficiency. Within this model, restoration of leptin to levels present
      prior to weight loss should relieve much of the metabolic opposition to keeping weight off.
      Preliminary studies support this hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The failure of obesity treatments to sustain weight reduction is widely recognized. The
      central hypotheses of these studies are that: 1) Energy and neuroendocrine homeostatic
      systems are altered during the maintenance of a reduced body weight in a manner that favors
      weight regain; 2) These changes occur because weight-reduced individuals are in a state of
      relative leptin deficiency due to loss of body fat; and 3) Therefore these changes
      accompanying the maintenance of a reduced body weight will be reversed if circulating leptin
      concentrations are restored to those that were present prior to weight reduction. Maintenance
      of a reduced body weight is associated with integrated autonomic and neuroendocrine changes
      that reduce energy expenditure and increase food intake in a manner that is similar to that
      seen in rodents and humans who are deficient in, or resistant to, the adipocyte-derived
      hormone leptin.

      Systemic leptin administration to leptin-deficient rodents and humans reverses the metabolic
      (hypometabolism, hyperphagia), autonomic (increased parasympathetic and decreased sympathetic
      nervous system tone), and neuroendocrine changes that characterize the leptin-deficient
      state. The proposed studies focus on the neuroendocrine, autonomic, and metabolic changes
      that characterize the reduced-obese individual, and the effects on these phenotypes of
      restoration of circulating concentrations of leptin to levels present prior to weight loss.

      Healthy lean and overweight subjects are admitted to the General Clinical Research Center at
      Columbia University Medical College and placed on a liquid formula diet. Calories are
      adjusted until weight is stable and then subjects undergo testing of neuroendocrine,
      autonomic, and metabolic function. All subjects undergo an in-patient 10% weight reduction.
      Subjects are studied in a single blind placebo control design in which they are studied at
      usual weight and while maintaining a 10% reduced weight. At either usual weight or reduced
      state subjects undergo a single blind crossover placebo/control study in which they receive
      placebo, leptin injections while on an isocaloric diet either at usual weight or following a
      10% weight loss.

      During each of these study periods, subjects will undergo detailed evaluation of 1) energy
      expenditure; 2) autonomic nervous system tone (serial blockade of sympathetic and
      parasympathetic inputs, heart rate variability analyses, and urinary catecholamine
      excretion); 3) hypothalamic-pituitary-thyroid, -adrenal and -gonadal, axis function; 4)
      adipose tissue gene expression; 5) other molecules (e.g., adiponectin, ghrelin, PYY) that may
      influence neuroendocrine and metabolic function. The results of these studies will further
      delineate the physiology of body weight regulation and of leptin.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed by sponsor. Lack of funding.
  </why_stopped>
  <start_date type="Actual">July 2002</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, single-blind, crossover study: half of the subjects had placebo first and half had leptin first. The order does not affect data analysis.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Energy Expenditure (TEE)</measure>
    <time_frame>Baseline, 11 weeks, 18 weeks</time_frame>
    <description>To measure the metabolic changes associated with maintenance of a reduced body weight (in kcal/day)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TEE/FFM</measure>
    <time_frame>Baseline, 11 weeks, 18 weeks</time_frame>
    <description>To measure the total energy expenditure/fat-free mass (FFM) (in kcal/kg).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Obesity</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Weight initial</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects undergo studies at their usual body weight which is used as a baseline against which to compare subjects following weight loss with or without leptin repletion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weight -10% placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are studied while at a 10% reduced body weight and receiving placebo injections for 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weight -10% leptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are studied while at a 10% reduced body weight and receiving leptin injections for 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous Placebo</intervention_name>
    <description>Twice daily injections of saline in the same volume as will be used for leptin injections.</description>
    <arm_group_label>Weight -10% placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leptin</intervention_name>
    <description>Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.</description>
    <arm_group_label>Weight -10% leptin</arm_group_label>
    <other_name>Metreleptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy lean or overweight males and females who have sustained their current weight
             for at least 6 months.

        Exclusion Criteria:

          -  Pregnancy

          -  Any illness or chronic medication that affect energy expenditure, neuroendocrine
             function, autonomic function or that would impair ability to tolerate a prolonged
             hospital stay including rapid weight reduction and vigorous exercise.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Rosenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, Gallagher D, Mayer L, Murphy E, Leibel RL. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005 Dec;115(12):3579-86.</citation>
    <PMID>16322796</PMID>
  </reference>
  <reference>
    <citation>Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab. 2002 May;87(5):2391-4.</citation>
    <PMID>11994393</PMID>
  </reference>
  <reference>
    <citation>Baldwin KM, Joanisse DR, Haddad F, Goldsmith RL, Gallagher D, Pavlovich KH, Shamoon EL, Leibel RL, Rosenbaum M. Effects of weight loss and leptin on skeletal muscle in human subjects. Am J Physiol Regul Integr Comp Physiol. 2011 Nov;301(5):R1259-66. doi: 10.1152/ajpregu.00397.2011. Epub 2011 Sep 14.</citation>
    <PMID>21917907</PMID>
  </reference>
  <reference>
    <citation>Hinkle W, Cordell M, Leibel R, Rosenbaum M, Hirsch J. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One. 2013;8(3):e59114. doi: 10.1371/journal.pone.0059114. Epub 2013 Mar 21.</citation>
    <PMID>23555620</PMID>
  </reference>
  <reference>
    <citation>Rosenbaum M, Leibel RL. 20 years of leptin: role of leptin in energy homeostasis in humans. J Endocrinol. 2014 Oct;223(1):T83-96. doi: 10.1530/JOE-14-0358. Epub 2014 Jul 25. Review.</citation>
    <PMID>25063755</PMID>
  </reference>
  <reference>
    <citation>Page-Wilson G, Reitman-Ivashkov E, Meece K, White A, Rosenbaum M, Smiley RM, Wardlaw SL. Cerebrospinal fluid levels of leptin, proopiomelanocortin, and agouti-related protein in human pregnancy: evidence for leptin resistance. J Clin Endocrinol Metab. 2013 Jan;98(1):264-71. doi: 10.1210/jc.2012-2309. Epub 2012 Nov 1.</citation>
    <PMID>23118421</PMID>
  </reference>
  <reference>
    <citation>Kissileff HR, Thornton JC, Torres MI, Pavlovich K, Mayer LS, Kalari V, Leibel RL, Rosenbaum M. Leptin reverses declines in satiation in weight-reduced obese humans. Am J Clin Nutr. 2012 Feb;95(2):309-17. doi: 10.3945/ajcn.111.012385. Epub 2012 Jan 11.</citation>
    <PMID>22237063</PMID>
  </reference>
  <results_reference>
    <citation>Rosenbaum M, Goldsmith RL, Haddad F, Baldwin KM, Smiley R, Gallagher D, Leibel RL. Triiodothyronine and leptin repletion in humans similarly reverse weight-loss-induced changes in skeletal muscle. Am J Physiol Endocrinol Metab. 2018 Nov 1;315(5):E771-E779. doi: 10.1152/ajpendo.00116.2018. Epub 2018 Jun 19.</citation>
    <PMID>29920214</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <results_first_submitted>June 18, 2019</results_first_submitted>
  <results_first_submitted_qc>August 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2019</results_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leptin</keyword>
  <keyword>Obesity</keyword>
  <keyword>Energy</keyword>
  <keyword>Autonomics</keyword>
  <keyword>Neuroendocrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Leptin Depletion Study Participants (Total)</title>
          <description>Each of the 22 participant went through the stages (arms) of obtaining the initial weight (Weight Initial), reducing weight maintenance (placebo injection), and repletion of leptin (leptin injection).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Weight Initial</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Weight -10% Placebo</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Weight -10% Leptin</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leptin Depletion Study Participants (Total)</title>
          <description>Each of the 22 participant went through the stages (arms) of obtaining the initial weight (Weight Initial), reducing weight maintenance (placebo injection), and repletion of leptin (leptin injection).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fa-free mass (FFM)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Energy Expenditure (TEE)</title>
        <description>To measure the metabolic changes associated with maintenance of a reduced body weight (in kcal/day)</description>
        <time_frame>Baseline, 11 weeks, 18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin Depletion Study Participants (Total)</title>
            <description>Each of the 22 participant went through the stages (arms) of obtaining the initial weight (Weight Initial), reducing weight maintenance (placebo injection), and repletion of leptin (leptin injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Energy Expenditure (TEE)</title>
          <description>To measure the metabolic changes associated with maintenance of a reduced body weight (in kcal/day)</description>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight initial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3131" spread="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight -10% placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2457" spread="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight -10% leptin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2766" spread="799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TEE/FFM</title>
        <description>To measure the total energy expenditure/fat-free mass (FFM) (in kcal/kg).</description>
        <time_frame>Baseline, 11 weeks, 18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin Depletion Study Participants (Total)</title>
            <description>Each of the 22 participant went through the stages (arms) of obtaining the initial weight (Weight Initial), reducing weight maintenance (placebo injection), and repletion of leptin (leptin injection).</description>
          </group>
        </group_list>
        <measure>
          <title>TEE/FFM</title>
          <description>To measure the total energy expenditure/fat-free mass (FFM) (in kcal/kg).</description>
          <units>kcal/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight initial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight -10% placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight -10% leptin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Leptin Depletion Study Participants (Total)</title>
          <description>Each of the 22 participant went through the stages of obtaining the initial weight (Weight Initial), reducing weight maintenance (placebo injection), and repletion of leptin (leptin injection). Since adverse events are not the primary focus of this study, the events were not collected and analyzed by the stages but for each participant during the entire study participation, therefore the data is combined.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Rosenbaum, MD</name_or_title>
      <organization>Professor of Pediatrics and Medicine at the Columbia University</organization>
      <phone>212-305-9949</phone>
      <email>mr475@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

